Small molecule (PROTAC degrader) · Degrader of Bruton's tyrosine kinase (BTK) · developed by BeOne Medicines
Tacabrutideg is an orally bioavailable PROTAC degrader that links a BTK-binding moiety to a cereblon E3 ligase-binding moiety, driving ubiquitination and proteasomal degradation of Bruton's tyrosine kinase. It is being studied in chronic lymphocytic leukemia and small lymphocytic lymphoma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06973187 | Phase 3 | Chronic Lymphocytic Leukemia | Recruiting | ONC |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
Updated Oct 25, 2026. Something wrong or missing? Report it on the ONC page.
See ONC's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
ONC catalysts and pipeline →